logo

SAGE(Delisted)

Sage Therapeutics·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 2
Bearish signal 0
Revenue Beats Expectation
EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000

About SAGE

Sage Therapeutics, Inc.

A biopharmaceutical company that develops drugs to treat life-threatening, rare central nervos system disorders

--
04/16/2010
07/18/2014
NASDAQ Stock Exchange
353
12-31
Common stock
215 First Street, Cambridge, Massachusetts 02142
--
Sage Therapeutics, Inc., was incorporated in Delaware on April 16, 2010. The company is a biopharmaceutical company with a mission to pioneer solutions that deliver life-changing brain health drugs so everyone can thrive. In addition to commercial products for postpartum depression, the company targets brain diseases and disorders in clinical development and early stages. As a company, the company focuses on brain health, and they are currently targeting two key central nervous system receptor systems, GABA and NMDA. The GABA receptor family is considered to be the main inhibitory neurotransmitter in the central nervous system, mediating downstream neural and bodily functions by activating GABAA receptors. The NMDA-type receptor of the glutamate receptor system is the main excitatory receptor system in the central nervous system. Dysfunction of these systems is associated with a wide range of central nervous system diseases.

Company Financials

EPS

SAGE has released its 2025 Q2 earnings. EPS was reported at -0.79, versus the expected -0.94, beating expectations. The chart below visualizes how SAGE has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

SAGE has released its 2025 Q2 earnings report, with revenue of 31.66M, reflecting a YoY change of 265.84%, and net profit of -49.65M, showing a YoY change of 51.73%. The Sankey diagram below clearly presents SAGE's revenue sources and cost distribution.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

No Data

You can ask Aime

No Data